Medical device industry giant Medtronic makes more moves in emerging markets, committing $6 million toward cardiovascular disease and diabetes research in India.

Pure-play medical device maker Medtronic (NYSE:MDT) invested further into its emerging market strategy, promising an additional $6 million for cardiovascular disease and diabetes research in India.

To be spread over 5 years, the funding will support treatment access and progress for 2 of the India's biggest health concerns. Cardiovascular disease is currently the No. 1 killer in India's urban and rural areas, and the country is home to more diabetics than any other country, according to a press release.